We have previously shown that a baseline cardio-oncologic thorough CV assessment of cancer patients scheduled to receive anti-VEGF agents was instrumental to optimize their CV profile (given the high prevalence of risk factors, frequently not adequately controlled) and to set up AH management. This evidence concerns the gene VEGFA and cancer.